Advisory committee will weigh Enbrel for psoriasis
Executive Summary
Amgen will present its case for approving its supplemental BLA for Enbrel (etanercept) before the Dermatologic and Ophthalmic Drugs Advisory Committee on June 18. Amgen is seeking approval of Enbrel for the treatment of moderate to severe psoriasis in the pediatric population. Enbrel, which is currently approved for rheumatoid arthritis and psoriasis, sold $951 million in its first quarter 1("The Pink Sheet," April 28, 2008, In Brief)